BiotechTube
SCA Pharma

SCA Pharma

Little Rock, United States· Est.
scapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $95M

Overview

SCA Pharma is a privately-held, revenue-generating services company operating in the FDA-regulated 503B outsourcing sector. Founded in 2003 and headquartered in Little Rock, Arkansas, the company manufactures and supplies sterile compounded generic injectables to healthcare facilities nationwide. Its strategy is built on operational excellence, state-of-the-art manufacturing facilities, and deep pharmacy supply chain expertise to address drug shortages and improve pharmacy efficiency. Under CEO Scott Luce, SCA Pharma is positioned for growth as healthcare systems increasingly rely on outsourced sterile compounding for cost and safety benefits.

Critical CareAnesthesiaPain ManagementLabor and Delivery

Technology Platform

FDA-registered 503B outsourcing facilities utilizing cGMP-compliant sterile compounding and aseptic filling processes for ready-to-use injectables and pre-filled syringes.

Funding History

2
Total raised:$95M
Debt$75M
Series A$20M

Opportunities

The growing trend of hospitals outsourcing sterile compounding to mitigate risk and reduce costs presents a major expansion opportunity.
Persistent drug shortages, particularly in generic injectables, create recurring demand for reliable 503B suppliers like SCA Pharma.
Expanding its product catalog and distribution through additional digital purchasing platforms can drive market penetration and customer convenience.

Risk Factors

Intense regulatory scrutiny as an FDA 503B facility means any significant compliance failure could result in severe operational and reputational damage.
The company faces competitive pressure from other large-scale 503B outsourcers and is vulnerable to pricing pressures from cost-conscious hospital systems.
Reliance on a stable supply of quality raw materials, especially for shortage drugs, presents a persistent supply chain risk.

Competitive Landscape

SCA Pharma competes in the 503B outsourcing market against other large-scale facilities such as Fagron Sterile Services, QuVa Pharma, and PharMEDium (now part of B. Braun). Competition is based on quality reputation, service reliability, product breadth, and price. The landscape is consolidating, with larger players seeking scale advantages, making SCA Pharma's operational excellence and customer focus critical differentiators.

More companies in Small Molecule Drugs →More companies in United States →